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Abstract 
The objectives of this study were to develop biodegradable polylactic-co-glycolic acid (PLGA) based injectable 
phase inversion in situ forming system for sustained delivery of triamcinolone acetonide (TA) and to conduct 
physicochemical characterization including in vitro drug release of the prepared formulations. TA (at 0.5%, 1% 
and 2.5% w/w loading) was dissolved in N-methyl-2-pyrrolidone (NMP) solvent and then incorporated 30% w/w 
PLGA (50/50 and 75/25) polymer to prepare homogenous injectable solution. The formulations were evaluated 
for rheological behaviour using rheometer; syringeability by Texture Analyser; water uptake and rate of implant 
formation by optical coherence tomography (OCT) microscope. Phase inversion in situ forming formulations were 
injected into PBS pH 7.3 to form an implant and release samples were collected and analysed for drug content 
using a HPLC method. All formulations exhibited good syringeability and rheological properties (viscosity: 0.19-
3.06 Pa.s) by showing shear thinning behaviour which enable them to remain as free flowing solution for ease 
administration. The results from OCT microscope demonstrated that thickness of the implants were increased with 
the increase in time and the rate of implant formation indicated the fast phase inversion. The drug release from 
implants was sustained over a period of 42 days. The research findings demonstrated that PLGA/NMP-based 
phase inversion in situ forming implants can improve compliance in patient’s suffering from ocular diseases by 
sustaining the drug release for a prolonged period of time and thereby reducing the frequency of ocular injections. 
Keywords In situ implant, ocular, ophthalmic, triamcinolone acetonide, PLGA, phase inversion  
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Introduction 
Posterior segment eye diseases often contributes to the most prevalent causes of visual impairment and blindness 
worldwide. The World Health Organization estimates that globally about 285 million people are visually impaired; 
39 million are blind and 246 million have low vision [1]. Majority of eye diseases that causes visual impairment 
typically originates in the posterior segment of the eye such as age-related macular degeneration (AMD), diabetic 
retinopathy (DR), diabetic macular edema (DME), uveitis and retinitis [2]. Treating these diseases is challenging 
owing to the extremely delicate nature of the tissues concerned and their relative inaccessibility. Regardless of 
aforementioned causes, ineffectiveness of conventional treatment also represents enormous challenges to the 
researchers owing to the poor absorption and therapeutic response of drug molecules associated with rapid pre-
corneal elimination and multiple protective barriers of the eye. As a result, frequent drug administration is required 
causing low patient’s compliance [3]. In order to overcome these shortcomings, intensive efforts have been 
devoted to the fabrication of new injectable drug delivery system aiming to achieve effective drug delivery to the 
targeted site of action, sustain the drug release and enhance bioavailability.  
Intravitreal delivery (IVD), a direct injection of therapeutic agents into the eyes, is a standard practice to 
treat posterior segment diseases. However, due to the chronic nature of the above conditions, and the short acting 
nature of available therapies, patients require frequent dosing (e.g., every 4-6 weeks) over many years. 
Furthermore, this route is also associated with severe side effects, such as high therapeutic dosage-induced ocular 
toxicity, pain and discomfort, vitreous haemorrhage and cataract development [3, 4].  
Currently, development of in situ forming implant (ISFI) has gained tremendous popularity as it avoids 
the need for frequent injections in the eye or surgical implantation. In contrast, ISFIs are injected as low viscous 
solution that transform to a solid depot or implant at the site of action which in turn controls drug delivery [6]. 
This stimulation of sol-to-gel transformation requires appropriate amount of triggers depending on the 
mechanisms i.e. solidifying organogels, cross-linking systems and phase separation/inversion system [4]. The 
phenomenon of phase separation from a solution occurs due to the changes in their environmental temperature, 
pH or by solvent exchange. In the present research, exclusively focused on the phase inversion-based ISFI by 
solvent exchange as they are easy to manufacture in few simple steps and does not require any trigger to stimulate 
the transformation and also they represent an excellent strategy for ocular controlled drug release applications. 
The phase inversion-based ISFI concept was first introduced by Dunn et al. (1999) [7] comprising a water 
insoluble polymer, dissolved with water miscible and physiologically biocompatible organic solvents incorporated 
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with a required drug [6]. Upon injection into aqueous medium such as vitreous humour of the eye, phase separation 
occurs with an influx of water fluid to the solid depot and outflow of organic solvents to surrounding tissue causing 
precipitation of polymer followed by entrapment of drug molecules within the matrix of polymer as it solidifies. 
Finally, the drug is being released slowly by diffusion and/or as the implants biodegrades (Fig. 1) [8, 9]. 
 
Fig. 1 Schematic representations of ISFI formation by solvent exchange technique and drug delivery. (Adopted 
and modified from Thakur et al. 2014) [5] 
 
The unique characteristics of polymer incorporated into the ISFI plays a vital role in the rate of drug release 
and magnitude of phase inversion dynamic. The key selection of polymers should possess physical and chemical 
stability, biocompatibility and water immiscibility that allow polymer precipitation and implant formation [9, 10]. 
Polylactic-co-glycolic acid (PLGA) has been among the most promising and attractive polymeric alternative 
which is used to facilitate the drug delivery system. This has been sparked by various advantages shown by the 
properties of the polymer such that it is physiologically biocompatible, biodegradable, and approved by USFDA 
[4, 6, 11]. Depending on the copolymer ratios and molecular weight, PLGA offers a wide range of degradation 
characteristics and burst release effects. Hence, PLGA 50/50 and PLGA 75/25 were selected to investigate the 
sustained delivery of triamcinolone acetonide (TA), which is used in the treatment of chronic ocular diseases such 
as AMD, DME and DR. The aim of the present research is to formulate and characterize PLGA based phase 
inversion ISFI consisting of TA. This technology could potentially enhance patient’s compliance by reducing the 
frequency of drug administration. 
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Materials and Methods 
 Materials 
Poly-lactic-co-glycolic acid (PLGA) (50/50 and 75/25) was purchased from Purac Biomaterials, Netherlands. N-
methyl-2-pyrrolidone (NMP) was purchased from Sigma Aldrich, England. Triamcinolone acetonide (TA) was 
obtained from BUFA, Netherlands. Phosphate buffer solution (PBS) was obtained from Sigma-Aldrich Company, 
England. Acetonitrile of HPLC grade was purchased from Fischer Scientific, United Kingdom. 
Preparation of Biodegradable Phase-Inversion Based ISFI  
The composition of prepared formulations is shown in Table 1. Briefly, the required amount of TA were accurately 
weighed and dissolved in NMP. Then, 30% w/w of PLGA 50/50 or PLGA 75/25 was incorporated into the solution 
and stirred overnight at 200 rpm to obtain homogenous and clear injectable solution. These solutions were 
transformed into a solid implant when injected into phosphate buffer solution (PBS), pH 7.3. 
                           Table 1 Composition of ISFI formulations containing different drug concentrations. 
 
 
 
 
 
 
HPLC method for TA analysis 
A stock solution of TA (1 mg/ml) was prepared by dissolving the drug in PBS, pH 7.3. It was then diluted to a 
series of drug concentrations ranging from 1 to 250 μg/ml. These solutions were analysed using Agilent 1260 
Infinity Quaternary System HPLC (Agilent Technologies Ltd., Stockport, UK) connected to UV/Visible 
spectrophotometer which was set at 236 nm. A reverse phase Agilent Zorbax C18 column (150 × 4.6 mm i.d., 5 
µm particle size) with Agilent Zorbax guard column held at 25°C (Agilent Technologies Ltd., Stockport, UK) was 
used for the chromatographic separation. The mobile phase consisted of a mixture of 60% water and 40% 
acetonitrile and was delivered at a flow rate of 0.8 ml/min. The injection volume was 20 µl. The calibration curve 
Formulation TA (%w/w) 
PLGA 50/50 
(%w/w) 
PLGA 75/25 
(%w/w) 
NMP 
(%w/w) 
F1-0% TA 0 30 - 70.0 
F1-0.5% TA 0.5 30 - 69.5 
F1-1.0% TA 1.0 30 - 69.0 
F1-2.5% TA 2.5 30 - 67.5 
F2-0% TA 0 - 30 70.0 
F2-0.5% TA 0.5 - 30 69.5 
F2-1.0% TA 1.0 - 30 69.0 
F2-2.5% TA 2.5 - 30 67.5 
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equation was derived from the areas of the TA absorbance peak plotted against respective drug concentration.  
This HPLC method was used to determine the % of drug release from the prepared ISFI formulations. 
Rheological characterisation of ISFI 
Viscosity measurements and behaviour 
The rheological behaviour of all the formulations was investigated using an AR 200 rheometer (T.A instruments, 
Surrey, UK) in flow mode at 21±0.1 °C, using 20 mm steel plate [6, 12]. A gap of 500 µm along with a constant 
force of 5.0 N were set. The formulations were exposed to a continuous shear rate ranging from 0-50/s. Viscosity 
was determined using power law set by the program. The measurements were carried out in triplicate. 
 
Dynamic viscoelastic measurement 
Stress sweep test was performed under oscillatory mode by applying oscillatory stress from 0-50 Pa at constant 
frequency of 0.1 Hz in order to determine the stability of formulations-linear viscoelasticity region (LVER). Then, 
a frequency sweep test was performed by exerting a constant sheer stress obtained from LVER (5 Pa) with 
increasing frequency from 0.1 to 1 Hz [11-13]. 
Syringeability Test 
A Texture Analyser (TA-TX2, Stable Micro Systems, Surrey, UK), set in compression mode, was used to 
determine the maximum forces and work (syringeability) required to inject the polymeric formulations at 21°C. 
The set-up of Texture Analyzer is shown in Fig. 2. The needles of 27G and 29G with two sample sizes of 0.1 ml 
and 0.2 ml were used. A downward force of 0.05 N was applied with plunger displacement of 60 mm (27G) and 
120 mm (29G). Work of syringeability was determined by the area under the curve derived from the resultant 
force-distance plot [14]. 
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Fig. 2 Schematic representation of Texture Analyzer set-up for syringeability test. 
Visualization of implants formation 
A Vivosight® optical coherence tomography (OCT) microscope (Michelson Diagnostics, Massachusetts, USA) 
was used to examine the behavior (water uptake) and rate of implant formation of blank formulations (F1-0% TA 
and F2-0% TA) at regular intervals of 1, 4, 7 and 24 h. The images captured were analysed using Image J software 
to measure the thickness of outer shell of the implants formed during solidification process [6, 14].  
In vitro drug release studies 
Prior to injection, the formulations were centrifuged at 3000 rpm for 1 min to ensure the solutions were free from 
bubbles. About 0.17 ml of formulation was gradually injected into glass vials containing 5 ml PBS, pH 7.3 and 
solid spherical implant was formed within a few seconds. Then, the vials were kept in an incubator at 37 °C and 
60 rpm. About 1 ml of sample was withdrawn at predetermined time intervals (1, 7, 10, 14, 21, 28, 35 and 42 
days) and analysed the samples to determine the % of drug release using HPLC. The remaining medium was 
removed and replaced with fresh medium [15]. The data obtained from in vitro drug release study was fitted into 
mathematical modelling equations (Table 2) to determine the release pattern and release mechanism of the drug 
from the prepared formulations. The best fit model of release pattern was considered with highest regression value 
(r2) of zero and first order. The regression values of Higuchi model which indicate diffusion mechanism and 
Hixon-crowell model which indicate erosion mechanism were compared to identify the release mechanism. The 
release mechanism is further confirmed by the slop value (n) of Korsemeyer-peppas model. 
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Table 2 Mathematical modelling equations used to determine release rate and mechanism of TA from ISFI. 
 
Mathematical model Equation 
Zero-order    
First-order  
Higuchi  
Hixson-Crowell  
Korsemeyer-Peppas  
Qt= Amount of drug released in time ‘t’; Q0= Initial amount of drug in 
the dosage form; Qt /Q∞ = fraction of drug released at time “t”; k0, K, kH, 
Ks and Kk = Release rate constants; n= release exponent (indicative of 
release mechanism) 
 
Statistical analysis 
The results are reported as mean±standard deviation (S.D.). The viscosity results of prepared formulations were 
treated statistically using one-way analysis of variance (ANOVA). When there was a statistically signiﬁcant 
difference, a post hoc Tukey’s honestly signiﬁcant difference (HSD) test was performed. A statistical signiﬁcant 
difference was considered at p<0.05. 
Results 
Calibration curve of TA 
The calibration curve of TA was showed linearity in the concentration range of 1-250 μg/ml with regression value 
of 0.999. The chromatogram of TA was shown in Fig. 3 and the retention time of TA was 10.42 min. 
 
 Fig. 3 HPLC chromatogram of TA at 236 nm. 
 
 
Qt/Q∞ ൌ ܭ݇ݐ௡
ܮ݋݃ ܳݐ ൌ ܮ݋݃ ܳ0 െ ܭݐ/2.303 
ܹ0ଵ/ଷ െܹݐଵ/ଷ ൌ ܭݏݐ 
ܳݐ ൌ ݇ு ݐଵ/ଶ 
ܳݐ ൌ ܳ଴ ൅ ݇଴t 
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Flow properties of ISFI formulations by rheological measurement 
 
Table 3 shows the flow dynamic properties of PLGA/NMP system. As shear rate increases from 0-50/s, viscosity 
of formulations was decreased. All polymeric solutions exhibited pseudoplastic (shear thinning) behaviour with a 
rate index of below 1. The viscosity of the formulations was increased from 0.29-0.83 Pa.s with the increase in 
drug concentrations from 0-2.5% for the formulations prepared using PLGA 50/50. However, there was no 
statistically significant difference (p>0.05) in the viscosity results of F1-0% TA to F1-0.5% TA and F3-1% TA. 
The viscosity of blank formulation prepared with PLGA 75/25 was higher (3.06 Pa.s) compared to the 
formulations loaded with TA at concentrations of 0.5-2.5% (0.19-0.28 Pa.s) and found to be statistically 
significant difference among all the formulations (p<0.05).  Higher viscosity with PLGA 75/25 is due to the co-
polymer type i.e. composition of lactide(LA)/glycolide(GA) ratio which breaks with the incorporation of drug 
molecule that reduces the polymer-polymer intersegmental interactions thereby reducing the viscosity in NMP 
whereas PLGA 50/50 which has less amount of LA content compared to PLGA 75/25 which shows less effect 
with increasing TA content.  
                    Table 3 Results of viscosity and rate index of different formulations. 
 
 
 
 
 
 
 
 
 
Viscoelastic measurements 
All the formulations have demonstrated the same trend where they experienced fluid-like behaviour at low 
frequencies (G”>G’) and gel-like behaviour at high frequencies (G’>G”). Transition point where G’=G”, ranging 
Formulation Viscosity (Pa.s) 
(Mean ± SD, N=3) 
Rate Index 
 
F1-0% TA 0.29 ± 0.02 0.916 
F1-0.5% TA 0.46 ± 0.04 0.989 
F1-1.0% TA 0.54 ± 0.05 0.904 
F1-2.5% TA 0.83 ± 0.06 0.835 
F2-0% TA 3.06 ± 0.22 0.466 
F2-0.5% TA 0.19 ± 0.04 0.975 
F2-1.0% TA 0.27 ± 0.04 0.960 
F2-2.5% TA 0.28 ± 0.05 0.951 
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between 0.3-0.8 Hz were observed as shown in Table 4. This indicates the tendency of the formulations to undergo 
sol-to-gel transformation at the particular cross-over frequency and continued to behave as a gel [14, 16].  
Table 4 Results of cross over frequency of different formulations. 
Formulation Frequency (Hz) 
Elastic modulus 
G’ (Pa) 
Viscous modulus 
G” (Pa) 
tan 
(delta) 
F1-0% TA 0.5042 0.7378 0.7608 1.031 
F1-0.5% TA 0.8162 1.820 1.871 1.028 
F1-1.0% TA 0.8715 2.091 2.134 1.020 
F1-2.5% TA 0.8715 2.118 2.125 1.003 
F2-0% TA 0.8347 2.304 2.282 0.990 
F2-0.5% TA 0.3756 0.4174 0.4224 1.012 
F2-1.0% TA 0.4859 0.6011 0.5944 0.989 
F2-2.5% TA 0.4306 0.5232 0.5244 1.002 
 
Syringeability test 
The syringeability and maximum force required to expel the formulations with different needle size are shown in 
Table 5. Work required to expel the formulations from 27G and 29G needle were increased with increasing sample 
volume from 0.1 ml to 0.2 ml. This is due to the higher resistance force associated with increasing plunger 
displacement. In addition, the maximum force required to expel both sample solutions increased with decreasing 
the needle inner diameter from 0.210 mm (27G) to 0.184 mm (29G).  
Visualisation of implant formation 
The OCT images are shown in Fig. 4. The outer shell thickness of implants (F1-0% TA and F2-0% TA) were 
increased with the time increment from 1 to 24 hours. This indicates the occurrence of fast phase inversion with 
rapid water uptake due to the strong hydrophilic nature of NMP, which causes the expansion of implant (Table 6) 
[14]. 
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                     Table 5 Results of work of syringeability and maximum forces required to expel different  
                                   volumes of  formulations with different needle size. 
 
Formulations Syringe 
(gauge) 
Volume 
(ml) 
Syringeability 
(Mean ± SD, N=3) 
Maximum Force (N) 
(Mean ± SD, N=3) 
F1-0% TA 
27 
0.1 49.01 ± 1.26 11.17 ± 0.29 
0.2 140.99 ± 6.51 14.65 ± 0.79 
29 
0.1 104.87 ± 0.20 31.08 ± 0.77 
0.2 246.74 ± 3.73 41.34 ± 0.99 
F2-0% TA 
27 
0.1 34.99 ± 3.44 7.22 ± 0.97 
0.2 75.48 ± 13.72 11.16 ± 0.05 
29 
0.1 80.14 ± 2.82 21.15 ± 0.74 
0.2 200.46 ± 3.02 25.80 ± 0.45 
 
 
Fig. 4 OCT images (scale bar 200 µm): (A) and (B) Thickness of PLGA 50/50 implants at 1 h and 24 h; (C) and 
(D) Thickness of PLGA 75/25 implants at 1 h and 24 h. The thickness of implants were increased with 
increase in time from 1 h to 24 h.  
 
Table 6 Thickness of outer shell of implants at different time intervals. 
 
 
 
 
 
 
 
 
Formulations Time (h) Thickness (µm) 
Mean ± SD, N=3 
F1-0% TA 
1 358.4 ± 24.61 
4 419.5 ± 16.15 
7 436.8 ± 14.55 
24 470.4 ± 27.54 
F2-0% TA 
1 286.5  ± 38.41 
4 305.1 ± 70.14 
7 334.5 ± 39.00 
24 368.7 ± 84.25 
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In vitro drug release studies 
In vitro drug release results are shown in and Fig. 5. The implants containing 0.5% TA of F1 and F2 exhibited a 
biphasic release pattern where there was a noticeable initial burst release of 14.7% and 28.91% respectively on 
the first day followed by a constant and sustained drug release of 60.24% and 63.15%, respectively in a period of 
42 days. In contrast, implants with 1% TA of F1 and F2 were released about 38.41% and 33.06%, respectively 
whereas implants with 2.5% TA of F1 and F2 were released 17.79% and 18.58% respectively over a period of 42 
days. These formulations demonstrated a consistent and uniform drug release without any initial burst release. 
The implant images captured at 1, 28 and 42 days of in vitro drug release studies are shown in Fig. 6. The images 
depicted that the implants were degraded over a time from 1 to 42 days which aid to the confirmation of 
biodegradation of the formed implant. Hence, no surgery is required as it results in natural loss of implant material 
after injection of implants. The drug release data was fitted into mathematical release kinetic models and the 
results demonstrated higher r2 value for first order and release exponent (n) value was greater than 0.6 for all the 
formulations (Table 7).  
 
 
      Fig. 5 Cumulative % of TA released from of ISFI containing different drug concentrations. 
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Fig. 6  (A), (B) and (C): PLGA 50/50 implants on the days of 1, 28 and 42; (D), (E) and (F):  PLGA 75/25 implants 
on the days of 1, 28 and 42.  
 
Table 7 Release kinetics results of TA loaded ISFI formulations. 
 
Discussion 
ISFI is one of the new and smart injectable drug delivery systems where the drug can be injected into the localised 
tissue as a liquid material in a minimally invasive manner which solidifies at the site of injection providing 
sustained drug delivery. Besides, the manufacturing steps are also simple and easy to scale-up, one of the simplest 
approaches to fabricate ISFI is phase inversion. The simple mechanism involved in sustaining the drug release 
through the phase inversion technique is the influx of non-solvent (water/body fluids) and efflux of water miscible 
organic solvent organic solvent (NMP) from the dose administered causes to precipitate the water immiscible 
polymer (PLGA) and entraps the drug in the matrix [5].  
Formulation Zero order (R2) 
First order 
(R2) 
Higuchi  
(R2) 
Hixon- 
Crowell (R2) 
Korsemeyer-Peppas 
R2 Slope (n) 
F1-0.5% TA 0.892±0.013 0.932 ±0.003 0.974±0.004 0.910 ±0.012 0.985±0.012 0.640±0.112 
F1-1.0% TA 0.913±0.028 0.936±0.026 0.984±0.003 0.929±0.027 0.998±0.002 0.750±0.005 
F1-2.5% TA 0.974±0.002 0.979±0.005 0.989±0.009 0.977±0.003 0.966±0.023 0.655±0.052 
F2-0.5% TA 0.872±0.077 0.885 ±0.069 0.840±0.060 0.815 ±0.070 0.985±0.010 0.645±0.044 
F2-1.0% TA 0.885 ±0.070 0.904±0.008 0.973±0.005 0.898±0.008 0.998±0.002 0.728±0.076 
F2-2.5% TA 0.958±0.017 0.965±0.015 0.986±0.005 0.963±0.016 0.994±0.006 0.674±0.059 
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 Triamcinolone acetonide, a corticosteroid having therapeutic potentials to treat the posterior segment 
of the ocular diseases i.e. intraocular edematous, DME, proliferative DR, retinal vein occlusions, uveitis including 
sympathetic ophthalmia, and exudative AMD. Currently, TA is administered as intravitreal injections which is 
having aforementioned potential side effects due to the frequency of the dose administration. Hence, in the present 
research work aimed to develop and characterize TA loaded ISFI using phase inversion technique.  
The rheological changes have made injection easy as the solutions remained free-flowing at room 
temperature and subsequently transformed to gel phase once they are injected into the eye [6, 14].  Both the volume 
of injection and gauge of the needle influences the syringeability and force required to administer the dose into 
the ocular region.The syringeability test results demonstrated that the implants could be administered through a 
small gauge needle. Hence, 27G needle was considered to be a better choice than 29G as it requires less force to 
inject the injection, which consequently enables easy administration without rendering injection difficulty or 
painful.  
The in vitro drug release results depicted that the relatively high initial burst release from formulations 
containing 0.5% TA of F1 and F2 was due to the fast transition of sol-to-gel formation which was driven by the 
rapid dissipation of highly water miscible organic solvent NMP into aqueous environment. Therefore, TA 
presented on the surface diffused out rapidly through large pores and water accessible channels which were created 
during fast phase separation [6].  
 However, uncommon phenomenon was observed where the rate of drug release decreases as drug 
concentration increases without any burst release. This could be explained by the hydrophobic nature of TA where 
it experienced more intense hydrophobic drug-polymer interaction. As a result, the drug molecules retained at the 
polymer matrix as it solidifies resulting in less diffusion of drug molecules. In addition, increased viscosity of the 
formulations together with the hydrophobicity of the matrix also contributed to this event where it retards the 
water uptake system and slowing phase inversion process. All these factors were assumed to exert a great impact 
to the rate of drug release, causing distinctive total releases of drug between the three formulations. Nevertheless, 
this is a good scenario in the aspects of therapeutic and economic view as it is able to prolong the effective lifespan 
of the implant. Furthermore, the less susceptibility to burst release is also beneficial where it minimize the potential 
local and systemic toxicity especially when dealing with narrow therapeutic index drugs.  
15 
 
 At day 1 of in vitro release study, the implants showed a smooth surface, and as the time progresses 
the implants appeared to be with porous surface and become smaller in size by day 42 (Fig. 6).  The degradation 
of implant mass was due to the hydrolytic process of the matrix and the drug, resulting in the release of water-
soluble PLGA degradation products (lactic and glycolic acid) which are eliminated from the body through Krebs 
cycle [4, 5]. Therefore, the entire polymer matrix was hydrolyzed leading to a homogenous degradation products 
formation and later bulk erosion [3].   
               All formulations exhibited first-order release pattern where the formulations showed higher r2 value for 
first-order release compared to zero-order. All the formulations showed higher r2 value for Higuchi model 
compared to Hixon-Crowell and it demonstrates that drug release followed the diffusion mechanism. The release 
mechanism was further confirmed by release exponent (n) value from Korsemeyer-Peppas model. The ‘n’ value 
was found to be greater than 0.6 for all the formulations which indicated that drug release from implants followed 
non-Fickian diffusion i.e. a combination of both diffusion and erosion mechanism.  
Conclusions 
Triamcinolone acetonide was successfully formulated as prolong released ISFI using PLGA and NMP. All the 
formulations exhibited good syringeabilty and rheological properties. The drug release was constant and sustained 
over a period of 42 days. Therefore, the developed formulations may improve patient’s compliance and 
convenience by reducing the frequency of drug administration and could be a viable alternative to existing 
treatments. 
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